UCB Biosciences, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Phase 2

Completed

Conditions: Epilepsy

Interventions: Drug: Lacosamide

First Posted Date: 2010-05-07

Last Posted Date: 2018-07-17

Lead Sponsor: UCB BIOSCIENCES, Inc.

Target Recruit Count: 39

Registration Number: NCT01118962

Locations: 🇺🇸
609, Bethesda, Maryland, United States
🇺🇸
601, Nashville, Tennessee, United States
🇺🇸
605, Lexington, Kentucky, United States

and more 16 locations

Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy

Phase 2

Completed

Conditions: Epilepsy

Interventions: Drug: Keppra XR

First Posted Date: 2009-08-19

Last Posted Date: 2015-08-06

Lead Sponsor: UCB BIOSCIENCES, Inc.

Target Recruit Count: 25

Registration Number: NCT00961441

An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy

Phase 2

Completed

Conditions: Epilepsy

Interventions: Drug: Lacosamide

First Posted Date: 2009-07-14

Last Posted Date: 2022-01-18

Lead Sponsor: UCB BIOSCIENCES, Inc.

Target Recruit Count: 366

Registration Number: NCT00938912

Locations: 🇺🇸
Sp848 016, Pittsburgh, Pennsylvania, United States
🇺🇸
Sp848 068, Cincinnati, Ohio, United States
🇺🇸
Sp848 061, Las Vegas, Nevada, United States

and more 66 locations

SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry

Completed

Conditions: Crohn's Disease

Interventions: Drug: Cimzia

First Posted Date: 2009-02-16

Last Posted Date: 2023-05-06

Lead Sponsor: UCB BIOSCIENCES, Inc.

Target Recruit Count: 3072

Registration Number: NCT00844285

Locations: 🇺🇸
C87075 517, Great Neck, New York, United States
🇺🇸
C87075 413, Great Neck, New York, United States
🇺🇸
C87075 237, Houston, Texas, United States

and more 194 locations

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

Phase 3

Completed

Conditions: Partial Epilepsies
Partial Onset Seizures

Interventions: Drug: lacosamide

First Posted Date: 2008-04-10

Last Posted Date: 2018-07-17

Lead Sponsor: UCB BIOSCIENCES, Inc.

Target Recruit Count: 97

Registration Number: NCT00655486

Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures

Phase 3

Completed

Conditions: Partial Onset Seizures
Partial Epilepsies

Interventions: Drug: lacosamide

First Posted Date: 2008-04-10

Last Posted Date: 2018-07-17

Lead Sponsor: UCB BIOSCIENCES, Inc.

Target Recruit Count: 100

Registration Number: NCT00655551

Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

Phase 3

Completed

Conditions: Partial Epilepsies

Interventions: Drug: lacosamide

First Posted Date: 2007-08-29

Last Posted Date: 2018-07-18

Lead Sponsor: UCB BIOSCIENCES, Inc.

Target Recruit Count: 308

Registration Number: NCT00522275

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

Phase 3

Completed

Conditions: Epilepsy

Interventions: Drug: Lacosamide

First Posted Date: 2007-08-27

Last Posted Date: 2018-07-19

Lead Sponsor: UCB BIOSCIENCES, Inc.

Target Recruit Count: 426

Registration Number: NCT00520741

Locations: 🇺🇸
61, Columbus, Ohio, United States
🇺🇸
32, Philadelphia, Pennsylvania, United States
🇺🇸
79, Atlanta, Georgia, United States

and more 155 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy